Medtronic (NYSE:MDT - Get Free Report) released its earnings results on Tuesday. The medical technology company reported $1.26 EPS for the quarter, beating analysts' consensus estimates of $1.25 by $0.01, RTT News reports. Medtronic had a return on equity of 13.68% and a net margin of 12.06%. The firm had revenue of $8.40 billion for the quarter, compared to analysts' expectations of $8.27 billion. During the same quarter in the prior year, the firm posted $1.25 earnings per share. The company's quarterly revenue was up 5.2% on a year-over-year basis. Medtronic updated its FY 2025 guidance to 5.440-5.500 EPS and its FY25 guidance to $5.44-5.50 EPS.
Medtronic Stock Performance
Shares of Medtronic stock traded down $2.50 during trading on Tuesday, hitting $85.09. 6,798,386 shares of the stock were exchanged, compared to its average volume of 6,246,340. Medtronic has a 12 month low of $74.66 and a 12 month high of $92.68. The company has a debt-to-equity ratio of 0.55, a quick ratio of 1.61 and a current ratio of 2.13. The stock has a market cap of $109.13 billion, a PE ratio of 28.72, a P/E/G ratio of 2.50 and a beta of 0.84. The stock's fifty day moving average is $89.42 and its 200 day moving average is $84.82.
Analysts Set New Price Targets
A number of equities research analysts have weighed in on MDT shares. Truist Financial lifted their target price on Medtronic from $90.00 to $93.00 and gave the company a "hold" rating in a research report on Monday, October 14th. Robert W. Baird raised their price target on Medtronic from $90.00 to $96.00 in a report on Friday. Needham & Company LLC reiterated a "hold" rating on shares of Medtronic in a research report on Monday. Wells Fargo & Company increased their target price on shares of Medtronic from $105.00 to $106.00 and gave the stock an "overweight" rating in a research note on Wednesday, August 21st. Finally, Barclays increased their price target on Medtronic from $104.00 to $105.00 and gave the stock an "overweight" rating in a research report on Thursday, August 22nd. One investment analyst has rated the stock with a sell rating, nine have given a hold rating, six have given a buy rating and one has given a strong buy rating to the company's stock. According to MarketBeat.com, the stock presently has a consensus rating of "Hold" and a consensus price target of $95.80.
Check Out Our Latest Stock Report on MDT
About Medtronic
(
Get Free Report)
Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients worldwide. Its Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; cardiac ablation products; insertable cardiac monitor systems; TYRX products; and remote monitoring and patient-centered software.
Read More
Before you consider Medtronic, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Medtronic wasn't on the list.
While Medtronic currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Which stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
